1
|
Saura C, Modi S, Krop I, Park YH, Kim SB, Tamura K, Iwata H, Tsurutani J, Sohn J, Mathias E, Liu Y, Cathcart J, Singh J, Yamashita T. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol 2024; 35:302-307. [PMID: 38092229 DOI: 10.1016/j.annonc.2023.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 08/02/2023] [Accepted: 12/04/2023] [Indexed: 02/25/2024] Open
Abstract
BACKGROUND Primary analysis of the multicenter, open-label, single-arm, phase II DESTINY-Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1). We report updated cumulative survival outcomes with a median follow-up of 26.5 months (data cut-off 26 March 2021). PATIENTS AND METHODS Patients with HER2-positive mBC resistant or refractory to T-DM1 received T-DXd 5.4 mg/kg intravenously every 3 weeks until disease progression, unacceptable adverse events, or withdrawal of consent. The primary endpoint was confirmed objective response rate (ORR) by independent central review (ICR). Secondary endpoints included overall survival (OS), duration of response (DoR), progression-free survival (PFS), and safety. RESULTS The ORR by ICR was 62.0% [95% confidence interval (CI) 54.5% to 69.0%] in patients who received T-DXd 5.4 mg/kg every 3 weeks (n = 184). Median OS was 29.1 months (95% CI 24.6-36.1 months). Median PFS and DoR were 19.4 months (95% CI 14.1-25.0 months) and 18.2 months (95% CI 15.0 months-not evaluable), respectively. Drug-related treatment-emergent adverse events (TEAEs) were observed in 183 patients (99.5%), and 99 patients (53.8%) had one or more grade ≥3 TEAEs. Adjudicated drug-related interstitial lung disease/pneumonitis occurred in 15.8% of patients (n = 29), of which 2.7% (n = 5) were grade 5. CONCLUSIONS These updated results provide further evidence of sustained antitumor activity of T-DXd with a consistent safety profile in heavily pretreated patients with HER2-positive mBC.
Collapse
Affiliation(s)
- C Saura
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
| | - S Modi
- Memorial Sloan Kettering Cancer Center, New York
| | - I Krop
- Yale Cancer Center, New Haven, USA
| | | | - S-B Kim
- Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - K Tamura
- Shimane University Hospital, Izumo
| | - H Iwata
- Aichi Cancer Center Hospital, Nagoya
| | - J Tsurutani
- Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan
| | - J Sohn
- Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea
| | - E Mathias
- Daiichi Sankyo, Inc., Basking Ridge, USA
| | - Y Liu
- Daiichi Sankyo, Inc., Basking Ridge, USA
| | - J Cathcart
- Daiichi Sankyo, Inc., Basking Ridge, USA
| | - J Singh
- Daiichi Sankyo, Inc., Basking Ridge, USA
| | | |
Collapse
|
2
|
Geyer CE, Untch M, Prat A, Rastogi P, Niikura N, Mathias E, McLean LA, Wang Y, Loibl S. Abstract OT1-02-03: Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05). Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-ot1-02-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background Preoperative chemotherapy in combination with trastuzumab and pertuzumab is a preferred regimen for treating patients (pts) with HER2-positive, invasive, early breast cancer (BC). Pts who have received such treatment but still have residual invasive disease in the breast or lymph nodes at surgery are at greater risk for disease recurrence or death than those with a pathological complete response. The antibody-drug conjugate (ADC) T-DM1 is approved as a postneoadjuvant treatment for pts with residual invasive disease (in the breast and/or axillary nodes) after optimal neoadjuvant chemotherapy and trastuzumab (or trastuzumab with pertuzumab). T-DXd is a potent HER2-targeted ADC with a humanized HER2 antibody attached to a membrane-permeable topoisomerase I inhibitor payload by a cleavable tetrapeptide-based linker and a drug-to-antibody ratio of ≈8. T-DXd is approved globally for the treatment of adult pts with HER2-positive, unresectable or metastatic BC who have received ≥2 prior anti-HER2-based regimens in the metastatic setting or had prior chemotherapy and are refractory to or intolerant of standard treatments. These approvals have been supported by results from DESTINY-Breast01, an open-label, international, multicenter, phase 2 study of T-DXd in patients with HER2-positive metastatic BC. In an updated data cutoff (June 8, 2020), T-DXd demonstrated an objective response rate (ORR) of 61.4% (113/184 pts) and a duration of response of 20.8 months in pts with HER2-positive (IHC 3+ or ISH+), unresectable or metastatic BC previously treated with T-DM1 (Modi et al. Cancer Res. 2021;81[4 suppl]:PD3-06). Yet, further unmet need exists in patients who do not achieve pathologic complete response to neoadjuvant treatment, as these patients have increased risk of recurrence. Here, we describe a randomized phase 3 trial evaluating T-DXd vs T-DM1 as postneoadjuvant treatment for high-risk pts with HER2-positive primary BC who have residual invasive disease following neoadjuvant therapy. Study Description DESTINY-Breast05 is a multicenter, open-label, randomized, phase 3 trial comparing the efficacy and safety of T-DXd with those of T-DM1 in pts with HER2-positive (IHC 3+ or ISH+, centrally confirmed on pretreatment biopsy), invasive BC with pathologic evidence of residual invasive disease in the breast or axillary lymph nodes after neoadjuvant therapy. Additionally, pts must have a higher residual risk for recurrence, following standard T-DM1, defined as either presenting with inoperable disease (clinical stages T4, N0-3, M0 or T1-3, N2-3, M0) or operable BC at presentation (clinical stages T1-3, N0-1, M0) with axillary node-positive disease after neoadjuvant chemotherapy and anti-HER2 treatment. Approximately 1600 pts will be randomly assigned (1:1) to T-DXd or T-DM1 from ≈ 400 sites globally. Randomization is stratified by operative status at presentation, hormone receptor status, pathologic nodal status following neoadjuvant therapy, and type of HER2-targeted neoadjuvant therapy (single vs dual). T-DXd 5.4 mg/kg or T-DM1 3.6 mg/kg will be administered intravenously once every 3 weeks for 14 cycles. Invasive disease-free survival based on investigator assessment is the primary efficacy endpoint. Secondary endpoints are overall survival, disease-free survival, distant recurrence-free interval, and brain metastasis-free interval. The pharmacokinetics of T-DXd, biomarkers, and health-related quality of life will also be evaluated (NCT04622319).
Citation Format: Charles E Geyer, Jr, Michael Untch, Aleix Prat, Priya Rastogi, Naoki Niikura, Elton Mathias, Lee Anne McLean, Yibin Wang, Sibylle Loibl. Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr OT1-02-03.
Collapse
Affiliation(s)
- Charles E Geyer
- NSABP Foundation and Houston Methodist Cancer Center, Houston, TX
| | - Michael Untch
- AGO B and Helios Hospital Berlin-Buch, Berlin, Germany
| | - Aleix Prat
- Hospital Clínic Barcelona, Barcelona, Spain
| | - Priya Rastogi
- NSABP Foundation and University of Pittsburgh, Pittsburgh, PA
| | - Naoki Niikura
- Department of Breast and Endocrine Surgery, Tokai University School of Medicine, Isehara, Japan
| | | | | | | | | |
Collapse
|
3
|
Geyer CE, Untch M, Prat A, Rastogi P, Niikura N, Mathias E, McLean LA, Wang Y, Loibl S. Abstract OT-03-01: Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05). Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-ot-03-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Preoperative chemotherapy in combination with trastuzumab and pertuzumab is a preferred regimen for treating patients (pts) with HER2-positive, invasive, early breast cancer (BC). Pts who have received such treatment but still have residual invasive disease in the breast or lymph nodes at surgery are at greater risk for disease recurrence or death than those with a pathological complete response. The antibody-drug conjugate (ADC) T-DM1 was recently approved as a postneoadjuvant treatment for pts with residual invasive disease (in the breast and/or axillary nodes) after optimal neoadjuvant chemotherapy and trastuzumab (or trastuzumab with pertuzumab). T-DXd is a potent HER2-targeted ADC with a humanized HER2 antibody attached to a membrane-permeable topoisomerase I inhibitor payload by a cleavable tetrapeptide-based linker and a drug-to-antibody ratio of ≈ 8. Recently, T-DXd was approved for the treatment of adult pts with HER2-positive, unresectable or metastatic BC who have received ≥ 2 prior anti-HER2─based regimens in the metastatic setting (US) or had prior chemotherapy and are refractory to or intolerant of standard treatments (Japan). These approvals were based on a phase 2 study in which T-DXd demonstrated an objective response rate (ORR) of 60.9% (112/184 pts) and duration of response of 14.8 months in pts with HER2-positive (IHC 3+ or ISH+), unresectable or metastatic BC previously treated with T-DM1 (Modi et al. N Engl J Med. 2020;382:610-621). Here, we describe a randomized phase 3 trial evaluating T-DXd vs T-DM1 as postneoadjuvant treatment for high-risk pts with HER2-positive primary BC who have residual invasive disease following neoadjuvant therapy.
Study Description
DESTINY-Breast05 is a multicenter, open-label, randomized, phase 3 trial comparing the efficacy and safety of T-DXd with those of T-DM1 in pts with HER2-positive (IHC 3+ or ISH+, centrally confirmed on pretreatment biopsy), invasive BC with pathological evidence of residual invasive disease in the breast or axillary lymph nodes after neoadjuvant therapy. Additionally, pts must be at higher risk for recurrence, having either inoperable (clinical stages T4, N0-3, M0 or T1-3, N2-3, M0) or operable BC at presentation (clinical stages T1-3, N0-1, M0) with axillary node-positive disease after optimal neoadjuvant chemotherapy and anti-HER2 treatment. The trial is recruiting pts from ≈ 400 sites globally. Approximately 1600 pts will be randomized (1:1) to T-DXd or T-DM1. Randomization is stratified by operative status, hormone receptor status, pathological nodal status following neoadjuvant therapy, and type of HER2-targeted neoadjuvant therapy (single vs dual). T-DXd 5.4 mg/kg or T-DM1 3.6 mg/kg will be administered intravenously once every 3 weeks for 14 cycles. Invasive disease-free survival based on investigator assessment is the primary efficacy endpoint; disease-free survival is the key secondary efficacy endpoint. Other secondary endpoints are overall survival, distant recurrence-free interval, and brain metastasis-free interval. Safety assessments include serious and treatment-emergent adverse events, physical examinations, vital signs, on-study chest imaging (to screen for pneumonitis), and clinical laboratory parameters. The pharmacokinetics of T-DXd, biomarkers, and health-related quality of life will also be evaluated. Long-term follow-up will continue after the primary analysis every 6 months until death, withdrawal of consent, loss to follow-up, or trial closure.
Citation Format: Charles E Geyer, Jr, Michael Untch, Aleix Prat, Priya Rastogi, Naoki Niikura, Elton Mathias, Lee Anne McLean, Yibin Wang, Sibylle Loibl. Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05) [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr OT-03-01.
Collapse
Affiliation(s)
- Charles E Geyer
- 1NSABP Foundation and Houston Methodist Cancer Center, Houston, TX
| | - Michael Untch
- 2AGO B and Helios Hospital Berlin-Buch, Berlin, Germany
| | - Aleix Prat
- 3Hospital Clínic Barcelona, Barcelona, Spain
| | - Priya Rastogi
- 4NSABP Foundation and University of Pittsburgh, Pittsburgh, PA
| | - Naoki Niikura
- 5Department of Breast and Endocrine Surgery, Tokai University School of Medicine, Kanagawa, Japan
| | | | | | | | | |
Collapse
|
4
|
Eugène M, Sauvant D, Nozière P, Viallard D, Oueslati K, Lherm M, Mathias E, Doreau M. A new Tier 3 method to calculate methane emission inventory for ruminants. J Environ Manage 2019; 231:982-988. [PMID: 30602259 DOI: 10.1016/j.jenvman.2018.10.086] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/23/2018] [Revised: 10/02/2018] [Accepted: 10/24/2018] [Indexed: 06/09/2023]
Abstract
Livestock is the main source of methane (CH4) emissions. It is important to accurately determine emissions from ruminants that meet standardized international guidelines for national greenhouse gas inventories. A new method to improve the accuracy of CH4 emissions that complies with IPCC rules for a Tier 3 method is described and evaluated. This method, developed by INRA (French Institute for Agricultural Research), was applied to the French inventory of CH4 emissions by ruminants and compared with the IPCC Tier 2 method. For enteric CH4, depending on the animal category, the INRA CH4 emission estimates lay between 88% and 114% of IPCC's. The INRA/IPCC ratio for enteric emission was close to unity and did not differ between methods (P = 0.43) for adult cows (i.e. most cattle). In France, feedlot manure is stored in aerobic conditions, and so the INRA/IPCC fit for manure emission was poorer (P < 0.05). The INRA/IPCC fit for enteric CH4 was very close between methods to that for total CH4 (P = 0.39), enteric CH4 representing 93% of total emissions. The main improvement is the use of a robust equation (from numerous data and diets), based on digestible organic matter intake (DOMI) corrected for the digestive interactions, to predict CH4 consistently from enteric and manure sources. It was developed for the French livestock inventory but is customizable for other countries. This new improved CH4 estimation method, based on equations from a large literature database, complies with IPCC rules for a Tier 3 method.
Collapse
Affiliation(s)
- M Eugène
- INRA, Université Clermont Auvergne, VetAgro Sup, UMR 1213 Herbivores, 63122, Saint-Genès-Champanelle, France.
| | - D Sauvant
- Agroparistech, UMR Mosar, 16 rue Claude-Bernard, 75005, Paris, France
| | - P Nozière
- INRA, Université Clermont Auvergne, VetAgro Sup, UMR 1213 Herbivores, 63122, Saint-Genès-Champanelle, France
| | - D Viallard
- INRA, Université Clermont Auvergne, VetAgro Sup, UMR 1213 Herbivores, 63122, Saint-Genès-Champanelle, France
| | - K Oueslati
- INRA, Université Clermont Auvergne, VetAgro Sup, UMR 1213 Herbivores, 63122, Saint-Genès-Champanelle, France
| | - M Lherm
- INRA, Université Clermont Auvergne, VetAgro Sup, UMR 1213 Herbivores, 63122, Saint-Genès-Champanelle, France
| | - E Mathias
- CITEPA, 42 rue, Paradis, 75009, Paris, France
| | - M Doreau
- INRA, Université Clermont Auvergne, VetAgro Sup, UMR 1213 Herbivores, 63122, Saint-Genès-Champanelle, France
| |
Collapse
|
5
|
Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer 2018; 124:2365-2372. [PMID: 29656442 DOI: 10.1002/cncr.31344] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Revised: 02/21/2018] [Accepted: 02/25/2018] [Indexed: 01/13/2023]
Abstract
BACKGROUND Hypertension (HTN) is an established class effect of vascular endothelial growth factor receptor (VEGFR) inhibition. In the phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) trial, HTN was the most frequent adverse event of lenvatinib, an inhibitor of VEGFR1, VEGFR2, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, FGFR4, platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and stem cell factor receptor (KIT). This exploratory analysis examined treatment-emergent hypertension (TE-HTN) and its relation with lenvatinib efficacy and safety in SELECT. METHODS In the multicenter, double-blind SELECT trial, 392 patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC) were randomized 2:1 to lenvatinib (24 mg/d on a 28-day cycle) or placebo. Survival endpoints were assessed with Kaplan-Meier estimates and log-rank tests. The influence of TE-HTN on progression-free survival (PFS) and overall survival (OS) was analyzed with univariate and multivariate Cox proportional hazards models. RESULTS Overall, 73% of lenvatinib-treated patients and 15% of placebo-treated patients experienced TE-HTN. The median PFS for lenvatinib-treated patients with (n = 190) and without TE-HTN (n = 71) was 18.8 and 12.9 months, respectively (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.39-0.88; P = .0085). For lenvatinib-treated patients, the objective response rate was 69% with TE-HTN and 56% without TE-HTN (odds ratio, 1.72; 95% CI, 0.98-3.01). The median change in tumor size for patients with and without TE-HTN was -45% and -40%, respectively (P = .2). The median OS was not reached for patients with TE-HTN; for those without TE-HTN, it was 21.7 months (HR, 0.43; 95% CI, 0.27-0.69; P = .0003). CONCLUSIONS Although HTN is a clinically significant adverse event that warrants monitoring and management, TE-HTN was significantly correlated with improved outcomes in patients with RR-DTC, indicating that HTN may be predictive for lenvatinib efficacy in this population. Cancer 2018;124:2365-72. © 2018 American Cancer Society.
Collapse
Affiliation(s)
- Lori J Wirth
- Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
| | - Makoto Tahara
- Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - Bruce Robinson
- Kolling Institute of Medical Research, University of Sydney, New South Wales, Australia
| | - Sanjeev Francis
- Cardiovascular Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
| | - Marcia S Brose
- Department of Otorhinolaryngology-Head and Neck Surgery, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Mouhammed Amir Habra
- Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Kate Newbold
- Thyroid and Radioactive Isotope Therapy Unit, Royal Marsden National Health Service Trust, London, United Kingdom
| | - Naomi Kiyota
- Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan
| | | | | | | | - Steven I Sherman
- Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Martin Schlumberger
- Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and University Paris-Saclay, Villejuif, France
| |
Collapse
|
6
|
Mathias E, Srinivas Murthy M. Pediatric Thermal Burns and Treatment: A Review of Progress and Future Prospects. Medicines (Basel) 2017; 4:medicines4040091. [PMID: 29232903 PMCID: PMC5750615 DOI: 10.3390/medicines4040091] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/24/2017] [Revised: 12/07/2017] [Accepted: 12/08/2017] [Indexed: 05/17/2023]
Abstract
Burn injuries are a devastating critical care problem. In children, burns continue to be a major epidemiologic problem around the globe resulting in significant morbidity and death. Apparently, treating these burn injuries in children and adults remains similar, but there are significant physiological and psychological differences. The dermal layer of the skin is generally thinner in neonates, infants, and children than in adults. Enhanced evaporative loss and need for isotonic fluids increases the risk of hypothermia in the pediatric population. The pain management of the children with major burns challenges the skills of the personnel of every unit. Managing these wounds requires intensive therapeutic treatment for multi-organ dysfunction, and surgical treatment to prevent sepsis and other complications that further delay wound closure. Alternatives to the practice of donor site harvest and autografting for the treatment of severe burns and other complex skin defects are urgently needed for both adult and pediatric populations. This review article focuses on thermal burn pathophysiology and pain management and provides an overview of currently approved products used for the treatment of pediatric burn wounds. A new promising approach has been presented as a first-line therapy in the treatment of burns to reduce surgical autografting in pediatric patients.
Collapse
Affiliation(s)
- Elton Mathias
- Department of Clinical Research, Mallinckrodt Pharmaceuticals, Bedminster, NJ 07921, USA.
| | | |
Collapse
|
7
|
|
8
|
Lovern D, Katzin B, Johnson K, Broadwell D, Miller E, Gates A, Deol P, Doing K, van Belkum A, Marshall C, Mathias E, Dunne WM. Antimicrobial binding and growth kinetics in BacT/ALERT® FA Plus and BACTEC® Aerobic/F Plus blood culture media. Eur J Clin Microbiol Infect Dis 2016; 35:2033-2036. [DOI: 10.1007/s10096-016-2759-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2016] [Accepted: 08/16/2016] [Indexed: 10/21/2022]
|
9
|
|
10
|
Köhler-Rollefson I, Rathore HS, Mathias E. Local breeds, livelihoods and livestock keepers’ rights in South Asia. Trop Anim Health Prod 2008; 41:1061-70. [DOI: 10.1007/s11250-008-9271-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2008] [Revised: 08/26/2008] [Accepted: 09/04/2008] [Indexed: 10/21/2022]
|
11
|
Abstract
Traditional 'animal doctors' are a substantial component of livestock healthcare systems in developing countries. However, in contrast to their counterparts in human ethnomedicine, such healers and their roles have been largely ignored by the modern veterinary community. While sometimes used as informants for community-based animal healthcare projects, traditional healers are rarely integrated into project training and delivery systems, and in many countries, they work in legal limbo. This paper overviews the little that is known about traditional livestock healers and their practices and argues that they represent a valuable, but as yet untapped, resource for extending many aspects of basic animal healthcare, especially to poor and smallholder producers in remote or difficult environments. Finally, the authors suggest broad steps for integrating these healers into conventional systems.
Collapse
Affiliation(s)
- E Mathias
- Integrated Livestock Development and Indigenous Knowledge, Weizenfeld 4, 51467 Bergisch Gladbach, Germany
| | | |
Collapse
|
12
|
Abstract
Gliding flight is a postural activity which requires the wings to be held in a horizontal position to support the weight of the body. Postural behaviors typically utilize isometric contractions in which no change in length takes place. Due to longer actin-myosin interactions, slow contracting muscle fibers represent an economical means for this type of contraction. In specialized soaring birds, such as vultures and pelicans, a deep layer of the pectoralis muscle, composed entirely of slow fibers, is believed to perform this function. Muscles involved in gliding posture were examined in California gulls (Larus californicus) and tested for the presence of slow fibers using myosin ATPase histochemistry and antibodies. Surprisingly small numbers of slow fibers were found in the M. extensor metacarpi radialis, M. coracobrachialis cranialis, and M. coracobrachialis caudalis, which function in wrist extension, wing protraction, and body support, respectively. The low number of slow fibers in these muscles and the absence of slow fibers in muscles associated with wing extension and primary body support suggest that gulls do not require slow fibers for their postural behaviors. Gulls also lack the deep belly to the pectoralis found in other gliding birds. Since bird muscle is highly oxidative, we hypothesize that fast muscle fibers may function to maintain wing position during gliding flight in California gulls.
Collapse
Affiliation(s)
- R A Meyers
- Department of Zoology, Weber State University, Ogden, Utah 84408-2505, USA
| | | |
Collapse
|
13
|
Bhalla RC, Toth KF, Tan E, Bhatty RA, Mathias E, Sharma RV. Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am J Hypertens 1996; 9:570-6. [PMID: 8783782 DOI: 10.1016/0895-7061(95)00356-8] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Metformin, an antidiabetic agent, potentiates insulin action and reduces insulin resistance. We examined the antihypertensive effects and vascular effects of metformin in spontaneously hypertensive rats (SHR). Wistar-Kyoto normotensive (WKY) and SHR were injected with metformin (100 mg/kg) or saline subcutaneously twice daily for 4 weeks. Blood pressure was recorded by a tail-cuff plethesmographic method. Metformin treatment significantly attenuated (P < .05) the increase in blood pressure in metformin treated SHR versus untreated control SHR. At the end of the experimental period of 4 weeks, metformin-treated SHR had a mean blood pressure that was 34 mm lower than that of untreated SHR. Metformin treatment had no significant effect on blood pressure in WKY rats. Treatment of SHR aortic smooth muscle (SM) cells with metformin (2 micrograms/mL) for 24 h significantly decreased (P < .05) arginine vasopressin- and thrombin- stimulated increase in [Ca2+]i. However, metformin treatment did not have a significant effect on the basal [Ca+]i. Incubation of SHR aortic SM cells with OH-L-arginine (25 to 100 mumol/L) for 24 h increased nitrite production in a dose dependent manner. Metformin (5 micrograms/mL) treatment of SM cells increased nitrite production at all concentrations of OH-L-arginine; however, differences were significant (P < .05) only at 25 and 50 mumol/L OH-L-arginine. These results suggest that metformin may be decreasing arterial pressure in the SHR, at least in part, by attenuating the agonist-stimulated [Ca2+]i response in SHR vascular smooth muscle cells.
Collapse
MESH Headings
- Animals
- Antihypertensive Agents/pharmacology
- Blood Pressure/drug effects
- Calcium/pharmacology
- Cells, Cultured
- Hypertension/genetics
- Hypertension/physiopathology
- Hypoglycemic Agents/pharmacology
- Image Processing, Computer-Assisted
- Male
- Metformin/pharmacology
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- Nitric Oxide/biosynthesis
- Rats
- Rats, Inbred SHR
- Rats, Inbred WKY
- Vascular Resistance/drug effects
Collapse
Affiliation(s)
- R C Bhalla
- Department of Anatomy, University of Iowa College of Medicine, Iowa City 52242, USA
| | | | | | | | | | | |
Collapse
|
14
|
|
15
|
|
16
|
|
17
|
Mathias E, Pincsohn A. IV. Zur Eklampsiefrage. Gynecol Obstet Invest 1925. [DOI: 10.1159/000301266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
18
|
|
19
|
|